EA200602196A1 - Производные пиразола, композиции, содержащие эти соединения, и способы применения - Google Patents

Производные пиразола, композиции, содержащие эти соединения, и способы применения

Info

Publication number
EA200602196A1
EA200602196A1 EA200602196A EA200602196A EA200602196A1 EA 200602196 A1 EA200602196 A1 EA 200602196A1 EA 200602196 A EA200602196 A EA 200602196A EA 200602196 A EA200602196 A EA 200602196A EA 200602196 A1 EA200602196 A1 EA 200602196A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
pyrazol
derivatives
connections
application
Prior art date
Application number
EA200602196A
Other languages
English (en)
Other versions
EA012431B1 (ru
Inventor
Эмма Р. Парми
Юйшэн Сюн
Цзянь Го
Жуй Лян
Линда Броканьер
Original Assignee
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Энд Ко., Инк. filed Critical Мерк Энд Ко., Инк.
Publication of EA200602196A1 publication Critical patent/EA200602196A1/ru
Publication of EA012431B1 publication Critical patent/EA012431B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Раскрыты пиразолы, содержащие присоединенную нафтильную группу. Данные соединения полезны для лечения диабета 2 типа и родственных состояний. Также раскрыты фармацевтические композиции и способы лечения.
EA200602196A 2004-06-04 2005-05-31 Производные пиразола, фармацевтические композиции и их применение EA012431B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57711604P 2004-06-04 2004-06-04
PCT/US2005/018828 WO2005121097A2 (en) 2004-06-04 2005-05-31 Pyrazole derivatives, compositions containing such compounds and methods of use

Publications (2)

Publication Number Publication Date
EA200602196A1 true EA200602196A1 (ru) 2007-06-29
EA012431B1 EA012431B1 (ru) 2009-10-30

Family

ID=35335786

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200602196A EA012431B1 (ru) 2004-06-04 2005-05-31 Производные пиразола, фармацевтические композиции и их применение

Country Status (34)

Country Link
US (2) US7598285B2 (ru)
EP (1) EP1756064B1 (ru)
JP (2) JP4108739B2 (ru)
CN (1) CN1964947A (ru)
AR (2) AR049291A1 (ru)
AT (1) ATE395338T1 (ru)
AU (2) AU2005252183B2 (ru)
BR (1) BRPI0511703B8 (ru)
CA (1) CA2566945C (ru)
CR (1) CR8766A (ru)
CY (1) CY1108544T1 (ru)
DE (1) DE602005006806D1 (ru)
DK (1) DK1756064T3 (ru)
EA (1) EA012431B1 (ru)
EC (1) ECSP067062A (ru)
ES (1) ES2306165T3 (ru)
GE (1) GEP20094605B (ru)
HR (1) HRP20080311T3 (ru)
IL (1) IL179754A (ru)
MA (1) MA28673B1 (ru)
MX (1) MXPA06014084A (ru)
MY (1) MY143599A (ru)
NI (1) NI200600290A (ru)
NO (1) NO339149B1 (ru)
NZ (1) NZ551405A (ru)
PE (1) PE20060427A1 (ru)
PL (1) PL1756064T3 (ru)
PT (1) PT1756064E (ru)
SI (1) SI1756064T1 (ru)
TN (1) TNSN06397A1 (ru)
TW (1) TWI293952B (ru)
UA (1) UA85884C2 (ru)
WO (1) WO2005121097A2 (ru)
ZA (1) ZA200609489B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069158A2 (en) 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
BRPI0511703B8 (pt) 2004-06-04 2021-05-25 Merck Sharp & Dhome Corp composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição
CN1993124A (zh) * 2004-07-22 2007-07-04 默克公司 取代吡唑、含有这种化合物的组合物及其应用
CN101300232A (zh) 2005-07-26 2008-11-05 默克公司 合成取代的吡唑的方法
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
WO2008087029A1 (en) * 2007-01-17 2008-07-24 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds with acat inhibition activity
KR20190126460A (ko) 2007-02-09 2019-11-11 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
WO2009005675A1 (en) * 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
WO2009035558A1 (en) * 2007-09-12 2009-03-19 Merck & Co., Inc. Process for the production of a crystalline glucagon receptor antagonist compound
US8436043B2 (en) 2008-03-05 2013-05-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
CA2718255C (en) 2008-03-11 2016-08-23 Aska Pharmaceutical Co., Ltd. Solid dispersion and pharmaceutical composition of the same, and production processes thereof
WO2009140342A1 (en) 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
KR101599089B1 (ko) 2008-08-13 2016-03-02 메타베이시스 테라퓨틱스, 인크. 글루카곤 길항제
RU2008135294A (ru) * 2008-08-29 2010-03-10 Дик Корпорейшн (Jp) Нафталиновые производные
US8436015B2 (en) * 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2350020B1 (en) * 2008-10-03 2014-08-13 Merck Sharp & Dohme Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists
WO2010093535A1 (en) 2009-02-12 2010-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2440553B1 (en) * 2009-06-12 2017-08-23 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
EP2480077B1 (en) 2009-09-22 2015-02-18 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
SG191040A1 (en) 2010-12-23 2013-08-30 Pfizer Glucagon receptor modulators
RS55225B1 (sr) 2011-02-08 2017-02-28 Pfizer Modulator glukagon receptora
ES2550345T3 (es) 2011-07-22 2015-11-06 Pfizer Inc. Moduladores del receptor de quinolinilglucagón
TW201427658A (zh) * 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
CN103933032B (zh) * 2013-12-30 2019-08-23 北京赛林泰医药技术有限公司 作为抗癌药物的吡唑类衍生物的使用方法和用途
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
KR102708864B1 (ko) 2016-08-30 2024-09-25 리제너론 파마슈티칼스 인코포레이티드 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
TWI763705B (zh) * 2016-09-06 2022-05-11 比利時商健生藥品公司 可作為升糖素受體拮抗劑之吲哚衍生物
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
EP3672620A1 (en) 2017-08-22 2020-07-01 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
EP3752249A1 (en) 2018-02-13 2020-12-23 Ligand Pharmaceuticals, Inc. Glucagon receptor antagonists

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) * 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
JPH11514651A (ja) 1995-10-31 1999-12-14 メルク エンド カンパニー インコーポレーテッド 置換ピリジルピロール、前記化合物を含む組成物及び使用方法
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
WO1998022108A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
EP0948257A4 (en) 1996-11-20 1999-12-29 Merck & Co Inc TRIARYL-SUBSTITUTED IMIDAZOLES, COMPOSITIONS CONTAINING THE SAME AND METHOD FOR THEIR USE
CA2271893A1 (en) 1996-11-20 1998-05-28 Linda L. Chang Triaryl substituted imidazoles as glucagon antagonists
DE69719544T2 (de) * 1996-12-12 2003-11-06 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
CN1253502A (zh) 1997-04-18 2000-05-17 G·D·西尔公司 利用环氧化酶－2的抑制物预防心血管疾病的方法
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6420427B1 (en) * 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
ATE389636T1 (de) 1997-12-19 2008-04-15 Amgen Inc Substituierte pyridin- und pyridazinderivate und ihre pharmazeutische verwendung
PL346660A1 (en) 1998-09-17 2002-02-25 Bristol Myers Squibb Co Method for treating atherosclerosis employing an ap2 inhibitor and combination
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
BR0013075A (pt) * 1999-08-10 2002-05-21 Bayer Agrochem Kk Derivados de tetrazolinona
DK1228067T3 (da) * 1999-11-10 2004-12-06 Takeda Chemical Industries Ltd 5-leddede heterocykliske forbindelser med hypoglykæmisk og hypolipidæmisk virkning
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
ATE362468T1 (de) * 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
WO2002040444A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) * 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
AU2002351730A1 (en) 2001-12-19 2003-06-30 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
WO2003053938A1 (en) 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
BR0307409A (pt) * 2002-02-01 2004-12-28 Dainippon Pharmaceutical Co Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
WO2004009158A2 (en) 2002-07-19 2004-01-29 Baxter International Inc. Systems and methods for performing peritoneal dialysis
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
EP1569915A4 (en) * 2002-12-04 2007-07-11 Merck & Co Inc SPIROCYCLIC UREAS, COMPOSITIONS CONTAINING SAME, AND METHODS OF USE
WO2004069158A2 (en) * 2003-01-27 2004-08-19 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
BRPI0409447A (pt) * 2003-04-14 2006-04-18 Inst For Pharm Discovery Inc ácidos fenilalcanóicos substituìdos
WO2004100875A2 (en) * 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
BRPI0511703B8 (pt) 2004-06-04 2021-05-25 Merck Sharp & Dhome Corp composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição
CN1993124A (zh) * 2004-07-22 2007-07-04 默克公司 取代吡唑、含有这种化合物的组合物及其应用
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Also Published As

Publication number Publication date
AU2005252183A1 (en) 2005-12-22
AU2008229701B2 (en) 2010-03-04
JP4733153B2 (ja) 2011-07-27
JP2008505062A (ja) 2008-02-21
NI200600290A (es) 2007-08-07
HRP20080311T3 (en) 2008-07-31
BRPI0511703A (pt) 2008-01-08
WO2005121097A3 (en) 2006-02-16
AU2008229701A1 (en) 2008-10-30
UA85884C2 (ru) 2009-03-10
CR8766A (es) 2007-08-28
US7598285B2 (en) 2009-10-06
CN1964947A (zh) 2007-05-16
JP4108739B2 (ja) 2008-06-25
GEP20094605B (en) 2009-02-10
NO339149B1 (no) 2016-11-14
TWI293952B (en) 2008-03-01
EP1756064B1 (en) 2008-05-14
MY143599A (en) 2011-06-15
PE20060427A1 (es) 2006-06-19
PL1756064T3 (pl) 2008-11-28
CA2566945C (en) 2010-09-21
ZA200609489B (en) 2007-10-31
BRPI0511703B8 (pt) 2021-05-25
IL179754A0 (en) 2007-05-15
WO2005121097A2 (en) 2005-12-22
TNSN06397A1 (en) 2008-02-22
ECSP067062A (es) 2007-01-26
CY1108544T1 (el) 2014-04-09
AR049291A1 (es) 2006-07-12
CA2566945A1 (en) 2005-12-22
US20050272794A1 (en) 2005-12-08
NO20070073L (no) 2007-03-05
US20090176854A1 (en) 2009-07-09
DE602005006806D1 (de) 2008-06-26
IL179754A (en) 2013-12-31
ES2306165T3 (es) 2008-11-01
MXPA06014084A (es) 2007-02-15
US7799818B2 (en) 2010-09-21
AU2008229701C1 (en) 2010-07-29
NZ551405A (en) 2009-06-26
EA012431B1 (ru) 2009-10-30
BRPI0511703B1 (pt) 2018-07-17
TW200604179A (en) 2006-02-01
ATE395338T1 (de) 2008-05-15
SI1756064T1 (sl) 2008-12-31
PT1756064E (pt) 2008-07-22
AU2005252183B2 (en) 2008-07-17
JP2008150388A (ja) 2008-07-03
AR088919A2 (es) 2014-07-16
EP1756064A2 (en) 2007-02-28
DK1756064T3 (da) 2008-09-22
MA28673B1 (fr) 2007-06-01

Similar Documents

Publication Publication Date Title
EA200602196A1 (ru) Производные пиразола, композиции, содержащие эти соединения, и способы применения
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
DE602005017895D1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
IS2376B (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
ATE433447T1 (de) Pyrimiidinverbindungen
WO2006086562A3 (en) Phenylazetidinone derivatives
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
EA200801565A1 (ru) Производные пиримидиниларилмочевины в качестве ингибиторов фактора роста фибробластов ( fgf-фактора )
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
SE0301700D0 (sv) Novel compounds
EA200802213A1 (ru) Способы лечения заболеваний крови
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
CY1111197T1 (el) Tριαζολες χρησιμες ως αναστολεις πρετεϊνικων κινασων
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
NO20071619L (no) Fremgangsmate for fremstilling av indazol forbindelse
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
SE0302139D0 (sv) Novel compounds
SE0402925D0 (sv) Novel Compounds

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU